Canadian Summer Oncology Update

June 23-25, 2017 | Fairmont Chateau Whistler

Welcome to the 6th Canadian Summer Oncology Update (formerly CCOCO) June 23 to 25, 2017. Please join us for this informative and interactive meeting at the beautiful alpine resort of Whistler, BC.

Once again the conference will showcase advances in the different tumor types including GI cancers (colorectal and gastric), breast, lung, renal cell cancers and myeloma. Other areas which will be explored will be onco-genomics as we move more into the era of personalized medicine – the BC experience will be described. Another timely topic is “Physician Assisted Dying” as Canada develops laws governing this.

Again, our goal of this conference is to bring oncologists as well as GPOs, residents, nurse practitioners and pharmacists with an interest in oncology from across Canada together in an environment where challenging cases can be discussed and best practices shared. In each educational segment, there will be a keynote presentation on new and relevant data followed by facilitators who will present a series of interactive case discussions with audience participation. By keeping the program interactive, our hope is to engage the audience to apply new knowledge to specific patient problems. Another objective is to provide multi-disciplinary strategies in management of tumor types which occurs frequently in the real world of oncology. Management of gastric cancer will be run like a tumor board involving the gastroenterologist, surgeon, medical and radiation oncologists on the panel.

Our invited faculty are experts in their field. They include :

Dr. Roslyn Juergens, Juravinski Cancer Centre, Hamilton, ON
Dr. Eric Lam, St. Paul’s Hospital, Vancouver, BC
Dr. Emile Woo, University of BC, Vancouver, BC
Dr. Shilo Lefresne, BCCA, Vancouver, BC
Dr. Jeffrey Rothenstein, Durham Regional Cancer Centre, Oshawa, ON
Dr. Janessa Laskin, BCCA, Vancouver, BC
Dr. Christopher Venner, Cross Cancer Institute, Edmonton, AB
Dr. Christian Kollmannsberger, BCCA, Vancouver, BC

Dr. Philip Champion, PEI Cancer Treatment Centre, Charlottetown, PEI
Dr. Jeff Kerrie, University of BC, Vancouver, BC
Dr. Sunil Verma, Tom Baker Cancer Centre, Calgary, AB
Dr. Simon Yu, Burnaby Hospital Regional Cancer Centre, Burnaby, BC
Dr. Michael Noble, Royal Columbian Hospital, New Westminster, BC
Dr. Jeremy Ho, Richmond Hospital Cancer Centre, Richmond, BC
Dr. Puneet Bains, Lions Gate Cancer Centre, North Vancouver, BC
Dr. John Yun, Richmond Cancer Centre, Richmond, BC

We are sure you will appreciate this lively and stimulating educational meeting.  We look forward to welcoming you to Whistler in June 2017.

 Sincerely, your Planning Committee:

Dr. Robert El-Maraghi, BSc., MD, FRCPC
Simcoe Muskoka Regional Cancer Program, Royal Victoria Regional Health Centre. Chair, Community Oncologists of Metro-Toronto

Dr. Wendy Lam, BSc. (Pharm), FRCPC
Director BC Community Oncology Trialists, Burnaby Hospital Regional Cancer Centre, Burnaby, BC

Dr. Barbara Melosky, MD, FRCPC
Associate Professor, University of British Columbia, Medical Oncologist, BC Cancer Agency, Vancouver, BC



In accordance with the guidelines governing the organization of CME, the following fees apply:
After May 16, 2017 – Physicians $250, Other Health Care Professionals $125

These fees cover meals for the participant during the conference.
Industry: Non sponsoring industry please contact Island Events Inc. (INDUSTRY is defined by 360inc. Planning Solutions as any person employed by a for-profit organization, including, biotech, financial, and pharmaceutical.)

Learning Objectives

At the completion of the meeting, attendees should be able to:

1.  Summarize therapeutic advances for colorectal cancers
2. Describe recent developments for gastro-esophageal cancers
3. Explore the multi-disciplinary management for gastro-esophageal cancers
4. Understand the different subtypes of lung cancer and their response to different therapies
5. Apply personalized onco-genomics to management of different cancers
6. Describe new therapies in myeloma and how best to sequence them
7. Recognize emerging area of immune-oncology in renal cell cancers
8.Appraise emerging clinical research in breast cancer in the newly diagnosed patient and those with metastatic disease
9. Recognize and start the dialogue on physician assisted dying
10.  Apply the therapeutic advances in different malignancies to patient care.
11.   Summarize the emerging data in various malignancies presented at recent medical meetings, including ASH, ASCO, San Antonio Breast Cancer, World Lung Conference, and World GI Conference.

Individual Session Objectives

1.  Summarize evolving biomarkers in metastatic CRC
2. Review best evidence for EGFR inhibitors vs VEGF inhibitors for 1st line EGFR wild type metastatic CRC
3. Evaluate metastatic CRC treatment benefit in era of targeted therapies
4. Determine overview for timing and sequencing therapies for metastatic CRC
5. Review update systemic therapies for metastatic gastro-esophageal cancer
6. Determine overview of invasive procedures useful for gastro-esophageal cancer
7. Assess most appropriate patients with gastro-esophageal cancer for surgery
8.Evaluate how best to sequence neo-adjuvant chemotherapy for patients with gastro-esophageal cancer
9. Describe new radiation techniques for management of gastro-esophageal cancer
10.  Determine guidelines for the use of radiation in gastro-esophageal cancer
11.   Apply evidence based medicine in clinical practice with case based discussion on treatment of gastro-esophageal cancers
12.  Integrate multi-disciplinary approach to management of gastro-esophageal cancer
13.  Examine the role of molecular profile targets to individualize treatment of metastatic lung cancer
14.  Assess management strategies for metastatic NSCLC patients including immune therapies
15.  Describe 3rd generation TKI’s in treatment of metastatic adenocarcinoma of the lung
16.  Examine use of onco-genomics to personalize medical care for different tumor types
17.   Summarize overview of new therapies for myeloma
18.  Discuss how best to sequence new therapies for myeloma
19.  Explore personalize treatment of myeloma based upon patient and disease specific characteristics
20. Explore emerging immune-therapies for renal cell cancer
21.  Determine the framework for sequencing therapies for renal cell cancer
22. Discuss physician assisted dying
23. Explore responsibilities for physician assisted dying to different disciplines of the cancer team
24. Describe promising novel agents and sub-type specific treatment algorithms for metastatic breast cancer
25. Discuss optimize treatment of metastatic ER+ breast cancer with dual pathway inhibition
26. Explore the utility of genomic and proteo-nomic diagnostic assays for management of breast cancer